Balancing Benefit/Risk in the Dermatology Disease Space
Time: 11:15 am
day: Day Two
Details:
- Considering whether the black box warning will stifle innovation across the JAK inhibitor class
- Correlating disease severity and quality of life with off-target effects of JAK inhibitors
- Rethinking how we define the black box warning to patients
